MNLO Menlo Therapeutics Inc.

5.45
-0.08  -1%
Previous Close 5.53
Open 5.49
Price To Book 0.86
Market Cap 126615403
Shares 23,232,184
Volume 75,367
Short Ratio
Av. Daily Volume 132,109

SEC filingsSee all SEC filings

  1. 8-K - Current report 181226638
  2. 8-K - Current report 181175032
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167090
  4. 8-K - Current report 181166541
  5. 8-K - Current report 181112171

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released December 10, 2018 - primary endpoint met. Phase 3 planned for 2019.
Serlopitant
Pruritus associated with psoriasis
Phase 3 data due 1H 2020.
Serlopitant
Pruritus associated with prurigo nodularis
Phase 2 data released October 8, 2018. Endpoints not met.
Serlopitant
Refractory chronic cough
Phase 2 data released April 9, 2018. Endpoints not met.
Serlopitant
Pruritus associated with atopic dermatitis

Latest News

  1. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
  2. Robbins Arroyo LLP: Menlo Therapeutics Inc. (MNLO) Misled Shareholders According to Class Action
  3. Market Trends Toward New Normal in Apptio, Menlo Therapeutics, Tanger Factory Outlet Centers, Cedar Realty Trust, Toll Brothers, and II-VI — Emerging Consolidated Expectations, Analyst Ratings
  4. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Inc.
  5. Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis
  6. This year's Bay Area IPO batch remains up 44% despite market turbulence
  7. Menlo Therapeutics to Participate in the 30th Annual Piper Jaffray Healthcare Conference
  8. INVESTOR ALERT: Kaskela Law LLC Announces Investigation of Menlo Therapeutics Inc. on Behalf of Investors - MNLO
  9. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Inc.
  10. Menlo Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
  11. Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Seaboard, Menlo, Super Micro, and NiSource on Behalf of Stockholders and Encourages Investors to Contact the Firm
  12. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Menlo Therapeutics Inc. (MNLO)
  13. Scott+Scott Attorneys at Law LLP Announces Investigation into Menlo Therapeutics Inc. (MNLO)
  14. Analysis: Positioning to Benefit within Matrix Service, Mersana Therapeutics, Quorum Health, Canopy Growth, Bristow Group, and Menlo Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results
  15. Menlo Stock Plunges on Phase II Chronic Cough Study Failure
  16. Today’s Research Reports on Stocks to Watch: Auris Medical Holding and Menlo Therapeutics
  17. Peninsula biotech coughs up 40 percent of its value on failed clinical trial
  18. [$$] Menlo Ends Development of Serlopitant in Refractory Chronic Cough

SEC Filings

  1. 8-K - Current report 181226638
  2. 8-K - Current report 181175032
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167090
  4. 8-K - Current report 181166541
  5. 8-K - Current report 181112171
  6. SC 13G - Statement of acquisition of beneficial ownership by individuals 181012221
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18985158
  8. 8-K - Current report 18985022
  9. 8-K - Current report 18923207
  10. SC 13G - Statement of acquisition of beneficial ownership by individuals 18822118